Cellular transplants in amyotrophic lateral sclerosis patients: an observational study

References

• Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688–700.
   PubMed Web of Science ®Google Scholar
• Rowland LP. Summing up: an action plan for ALS research. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(Suppl 1):141–3.
   PubMedGoogle Scholar
• Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet. 2007;369:2031–4.
   PubMed Web of Science ®Google Scholar
• Orrell RW. Understanding the causes of amyotrophic lateral sclerosis. N Engl J Med. 2007;357:822–3.
   PubMedGoogle Scholar
• Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3. doi:10.1186/1750-1172-4-3
   PubMed Web of Science ®Google Scholar
• Isacson O. The production and use of cells as therapeutic agents in neurodegenerative diseases. Lancet Neurol. 2003;2:417–24.
   PubMedGoogle Scholar
• Silani V, Leigh N. Stem therapy for ALS: hope and reality. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:8–10.
   PubMed Web of Science ®Google Scholar
• Svendsen CN, Langston JW. Stem cells for Parkinson disease and ALS: replacement or protection? Nat Med. 2004;10:224–5.
   PubMed Web of Science ®Google Scholar
• Swash M. The stem cell problem: expectations and reality. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:195–6.
   PubMedGoogle Scholar
• Bruijn LI, Cudkowicz M. Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev Neurother. 2006;6:417–28.
   PubMedGoogle Scholar
• Nayak MS, Kim YS, Goldman M, Keirstead HS, Kerr DA. Cellular therapies in motor neuron diseases. Biochim Biophys Acta. 2006;1762:1128–38.
   PubMed Web of Science ®Google Scholar
• Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol. 2007;211:27–35.
   PubMed Web of Science ®Google Scholar
• Lepore AC, Rauck B, Dejea C, Pardo AC, Rao MS, Rothstein JD, . Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci. 2008;11:1294–301.
   PubMed Web of Science ®Google Scholar
• Badayan I, Cudkowicz ME. Is it too soon for mesenchymal stem cell trials in people with ALS? Amyotroph Lateral Scler. 2008;9:321–2.
   PubMed Web of Science ®Google Scholar
• Chandran S. What are the prospects of stem cell therapy for neurology? Br Med J. 2008;337:1325–6.
   Google Scholar
• Kaspar BK. Mesenchymal stem cells as trojan horses for GDNF delivery in ALS. Mol Ther. 2008;16:1905–6.
   PubMedGoogle Scholar
• Mathews DJ, Sugarman J, Bok H, Blass DM, Coyle JT, Duggan P, . Cell-based interventions for neurologic conditions: ethical challenges for early human trials. Neurology. 2008;71:288–93.
   PubMed Web of Science ®Google Scholar
• Slavin S, Kurkalli BGS, Karussis D. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg. 2008;110:943–6.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Svendsen CN. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci. 2008;31:192–8.
   PubMed Web of Science ®Google Scholar
• Vincent AM, Sakowski SA, Schuyler A, Feldman EL. Strategic approaches to developing drug treatments for ALS. Drug Discov Today. 2008;13:67–72.
   PubMed Web of Science ®Google Scholar
• Andrews J. Amyotrophic lateral sclerosis: clinical management and research update. Curr Neurol Neurosci Rep. 2009;9:59–68.
   PubMed Web of Science ®Google Scholar
• Benatar M, Kurent J, Moore DH. Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2009;1:CD006153. doi: 10.1002/14651858
   Google Scholar
• Brooks BR. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol. 2009;65(Suppl 1):S17–23.
   Web of Science ®Google Scholar
• Sendtner M. Stem cells: tailor-made diseased neurons. Nature. 2009;457:269–70.
   PubMedGoogle Scholar
• Lepore AC, Maragakis NJ. Targeted stem cell transplantation strategies in ALS. Neurochem Int. 2007;50:966–75.
   PubMedGoogle Scholar
• Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, Aebischer P, . GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE. 2007;2:e689. doi:10.1371/journal.pone.0000689
   PubMed Web of Science ®Google Scholar
• Svendsen C. Stem cells and Parkinson's disease: toward a treatment, not a cure. Cell Stem Cell. 2008;2:412–13.
   PubMedGoogle Scholar
• Suzuki M, McHugh J, Tork C, Shelley B, Hayes A, Bellantuono I, . Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther. 2008;16:2002–10.
   PubMed Web of Science ®Google Scholar
• Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, . GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther. 2005;16:509–21.
   PubMed Web of Science ®Google Scholar
• Julien JP, Kriz J. Transgenic mouse models of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762:1013–24.
   PubMed Web of Science ®Google Scholar
• Heidersbach A, Gaspar-Maia A, McManus MT, Ramalho-Santos M. RNA interference in embryonic stem cells and the prospects for future therapies. Gene Ther. 2006;13:478–86.
   PubMedGoogle Scholar
• Vercelli A, Garbossa D, Mereuta M, Muraca G, Mareschi K. Rustichelli D, . Transplantation of human mesenchymal stem cells into the lumbar spinal cord of G93A mice. FENS Abstr., 3, A163.12, 2006.
   Google Scholar
• Vercelli A, Mereuta OM, Garbossa D, Muraca G, Mareschi K, Rustichelli D, . Human mesenchymal stem cell transplantation extends survival, improved motor performance and decreases neuroinflamation in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2008;31:395–405.
   PubMed Web of Science ®Google Scholar
• Cabanes C, Bonilla S, Tabares L, Martínez S. Neuroprotective effect of adult hematopoietic stem cells in a mouse model of motoneuron degeneration. Neurobiol Dis. 2007;26:408–18.
   PubMed Web of Science ®Google Scholar
• Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, . ‘Rejuvenation’ protects neurons in mouse models of Parkinson's disease. Nature. 2007;447:1081–6.
   PubMed Web of Science ®Google Scholar
• Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci. 2007;10:608–14.
   PubMed Web of Science ®Google Scholar
• Habisch HJ, Janowski M, Binder D, Kuzma-Kozakiewicz M, Widmann A, Habich A, . Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: limited intraparenchymal migration and survival narrows therapeutic effects. J Neural Transm. 2007;114:1395–406.
   PubMed Web of Science ®Google Scholar
• Julien JP. ALS: astrocytes move in as deadly neighbors. Nat Neurosci. 2007;10:535–7.
   PubMed Web of Science ®Google Scholar
• Kim SU. Genetically engineered human neural stem cells for brain repair in neurological diseases. Brain Dev. 2007;29:193–201.
   PubMed Web of Science ®Google Scholar
• Zhao CP, Zhang C, Zhou SN, Xie YM, Wang YH, Huang H, . Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy. 2007;9:414–26.
   PubMed Web of Science ®Google Scholar
• Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, . Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321:1218–21.
   PubMed Web of Science ®Google Scholar
• Hedlund E, Hefferan MP, Marsala M, Isacson O. Cell therapy and stem cells in animal models of motor neuron disorders. Eur J Neurosci. 2007;26:1721–37.
   PubMed Web of Science ®Google Scholar
• Hedlund E, Isacson O. ALS model glia can mediate toxicity to motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3:575–6.
   PubMedGoogle Scholar
• Marchetto MC, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3:649–57.
   PubMed Web of Science ®Google Scholar
• Huang H, Chen L, Wang H, Xiu B, Li B, Wang R, . Influence of patients’ age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J (Engl). 2003;116:1488–91.
   PubMed Web of Science ®Google Scholar
• Cedarbauma JM, Stamblera N, Maltab E, Fullerb C, Hiltb D, Thurmond B, Nakanishi A, BDNF ALS Study Group (Phase III). The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13–21.
   PubMedGoogle Scholar
• Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology. 1998;50:66–72.
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psych. 2006;77:390–2.
   PubMed Web of Science ®Google Scholar
• Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25:709–14.
   PubMed Web of Science ®Google Scholar
• Van den Berg L. Unproven cell-based treatment for ALS/MND: lessons from Beijing. Amyotroph Lateral Scler. 2007;8(Suppl 1):32(Abstr).
   Google Scholar
• http://www.mndassociation.org/research/for_researchers/internationalsymposium/18th_international_symposium/my_symposium/daily_bulletins/unproven.html. Mel Barry. Unproven cell-based treatments for ALS/MND: Lessons from Beijing. 2007. MND Association. Toronto. Date the web was accessed 7.04.2010
   Google Scholar
• Bedlack R, Hardiman O. ALSUntnagled (ALSU): a scientific approach to off-label treatment options for people with ALS using tweets and twitters. Amyotroph Lateral Scler. 2009;10:129–30.
   PubMed Web of Science ®Google Scholar
• Janson CG, Ramesh TM, During MJ, Leone P, Heywood J. Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J Hematother Stem Cell Res. 2001;10:913–5.
   PubMedGoogle Scholar
• Chen L, Huang H, Zhang J, Zhang F, Liu Y, Xi H, . Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2007;21:961–6.
   PubMedGoogle Scholar
• Mazzini L, Mareschi K, Ferrero I, Vassallo E, Oliveri G. Nasuelli N, . Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci. 2008;265:78–83.
   PubMed Web of Science ®Google Scholar
• Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, . Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008;71:1326–34.
   PubMed Web of Science ®Google Scholar
• Deda H, Inci M, Kurekci A, Sav A, Kayıhan K, Ozgun E, . Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy. 2008;15:1–8.
   Google Scholar
• Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy. 2009;3:1–9.
   Google Scholar
• Huang H, Chen L, Xi H, Wang Q, Zhang J, Liu Y, . [Olfactory ensheathing cells transplantation for central nervous system diseases in 1255 patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009;23:14–20
   PubMedGoogle Scholar
• http://www.xcell-center.com/treatments/diseases-treated/als.aspx. XCell-Center. Stem cell treatment of Amyotrophic Lateral Sclerosis. 2010. XCell-Center. Germany. Date the web was accessed 7.04.2010.
   Google Scholar
• Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Del Bo R, . Motoneuron transplantation rescues the phenotype of SMARD1 (spinal muscular atrophy with respiratory distress type 1). J Neurosci. 2009;29:11761–71.
   PubMedGoogle Scholar
• Deshpande DM, Kim YS, Martinez T, Carmen J, Dike S, Shats I, . Recovery from paralysis in adult rats using embryonic stem cells. Ann Neurol. 2006;60:32–44.
   PubMed Web of Science ®Google Scholar
• Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, . Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2006;103:16021–6.
   PubMed Web of Science ®Google Scholar
• Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, . Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389–92.
   PubMed Web of Science ®Google Scholar
• Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Ronchi D, . Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain. 2010;133:465–81.
   PubMed Web of Science ®Google Scholar
• Silani V, Corbo M, Ciammola A, Polli E. Stem-cell therapy for amyotrophic lateral sclerosis. Lancet. 2004;364:200–2.
   PubMed Web of Science ®Google Scholar
• Lo B, Kriegstein A, Grady D. Clinical trials in stem cell transplantation: guidelines for scientific and ethical review. Clin Trials. 2008;5:517–22.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, . EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005;12:921–38.
   PubMed Web of Science ®Google Scholar